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ABSTRACT
Risk-factors for bloodstream infections caused by
extended-spectrum b-lactamase (ESBL)-produc-
ing Escherichia coli were investigated using an
exploratory case-double control study in which 43
cases (70% producing CTX-M enzymes) were
compared with: (i) 86 patients with bacteraemia
caused by non-ESBL-producing E. coli; and (ii) 86
hospitalised patients. Previous follow-up as an
outpatient, urinary catheterisation and use of
oxyimino-b-lactams or fluoroquinolones were
independent risk-factors for ESBL-producing
E. coli among patients with E. coli bacteraemia,
and previous use of oxyimino-b-lactams or fluoro-
quinolones were also independent risk-factors
among hospitalised patients. These findings may
help in identifying patients at greater risk for
bloodstream infection caused by ESBL-producing
E. coli in endemic areas.
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Escherichia coli producing extended-spectrum
b-lactamases (ESBLs) are an emerging cause of
community and nosocomial infection, and are
associated particularly with the worldwide spread
of CTX-M types of ESBL [1,2]. The treatment
options for patients with infections caused by these
organisms are limited. As is the case with ESBL-
producing Klebsiella pneumoniae [3], treatment with
cephalosporins or fluoroquinolones of blood-
stream infections caused by ESBL-producing
E. coli is associated with a poorer prognosis than
is carbapenem therapy [4]. As bacteraemia caused
by E. coli is frequent, this could result in a signif-
icant increase in the use of carbapenems, which
might contribute to further spread of carbapenem
resistance. Knowledge of risk-factors for bacter-
aemia caused by ESBL-producing E. coli might
help to identify patients at higher risk, who should
therefore receive empirical coverage against these
organisms, and could also permit the identification
of potential intervention strategies. The objective of
this study was therefore to investigate the risk-
factors for bacteraemia caused by ESBL-producing
E. coli in a non-epidemic situation.
A case-double control study with prospective
recruitment was carried out in the Hospital Uni-
versitario Virgen Macarena, a 950-bed hospital in
Sevilla, Spain that provides care for a population of
550 000. The case-patient group included all 43
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episodes of bloodstream infections caused by
ESBL-producing E. coli that were diagnosed in this
hospital between January 2001 and March 2005.
Microbiological characterisation of the isolates and
outcome of the case-patients have been described
previously [4]; all isolates were clonally unrelated,
and of 37 isolates that were characterised, 24
produced CTX-M-14, one CTX-M-9, ten SHV-12
and two SHV-4 [4].
In case-control studies that investigate the risk-
factors for infections caused by resistant bacteria,
the selection of controls among patients infected
with the susceptible organism tends to overesti-
mate the ORs for previous antimicrobial use [5].
Thus, the present study compared cases with two
groups of controls (with two controls for each
case in each group): (i) control group 1 included
randomly chosen patients with bacteraemia
caused by non-ESBL-producing E. coli who had
been admitted to the same specialty as the
corresponding case-patient; and (ii) control
group 2 included randomly chosen patients who
had been admitted to the same specialty and who
had a length of a hospital stay that was at least as
long as that of the corresponding case-patient
before the onset of bacteraemia.
Variable data collected were age, gender,
previous healthcare, type and severity of
co-morbidities (using the Charlson index) [6],
invasive procedures, use of antimicrobial agents
in the preceding 2 months, source of bacteraemia
(using CDC criteria) [7], and the presence of
severe sepsis or septic shock [8]. Bloodstream
infections were primarily defined as nosocomial
or community-acquired [7]; community-acquired
episodes were further classified as healthcare-
associated or strictly community-acquired [9]. The
study was approved by the local Ethical Com-
mittee.
The Mann–Whitney U-test and the chi-square
test (or Fisher’s exact test when appropriate) were
used to compare continuous and categorical
variables, respectively. Multivariate conditional
logistic regression (STAT v.8.0; Stata Corp., Col-
lege Station, TX, USA) for datasets 1:2 was used to
identify independent risk-factors associated with
bacteraemia caused by ESBL-producing E. coli.
Variables that were significantly associated in the
univariate analysis, and those with an epidemio-
logical rationale, were included in the initial
models, and were selected through a stepwise
backward process.
In total, there were 43 cases and 86 patients in
each control group. Univariate and multivariate
analyses of variables associated with bacteraemia
caused by ESBL-producing E. coli are shown in
Tables 1 and 2. Considering the risk-factors
identified using control group 1, six cases (14%)
had none of the four risk-factors, 15 (35%) had
one, and 22 (51%) had two or more. There were
no differences in the presumed origin of bacter-
aemia among cases and controls: urinary tract in
Table 1. Univariate analysis of risk-factors for bacteraemia caused by extended-spectrum b-lactamase-producing
Escherichia coli
Cases (n = 43)
Control group 1
(n = 86) OR (95% CI) p
Control group 2
(n = 86) OR (95% CI) p
Male gender 30 (70%) 47 (55%) 1.9 (0.8–4.1) 0.09 50 (58%) 1.6 (0.7–3.6) 0.2
Age >65 years 27 (63%) 57 (66%) 0.8 (0.4–1.8) 0.6 44 (51%) 1.6 (0.7–3.4) 0.2
Previous follow-up as an outpatient 25 (58%) 28 (33%) 2.8 (1.3–6.1) 0.005 40 (47%) 1.5 (0.7–3.3) 0.2
Charlson index >2 27 (63%) 42 (49%) 1.7 (0.8–3.7) 0.1 31 (36%) 2.4 (1.4–6.3) 0.004
Diabetes mellitus 14 (33%) 32 (37%) 0.8 (0.3–1.7) 0.6 16 (19%) 2.1 (0.9–4.8) 0.07
Chronic renal insufficiency 6 (14%) 3 (4%) 4.4 (1.0–18.9) 0.05 3 (4%) 4.4 (1.0–18.9) 0.05
Chronic liver disease 7 (16%) 11 (13%) 1.3 (0.4–3.7) 0.5 6 (7%) 2.5 (0.8–8.2) 0.1
Neoplasia 19 (44%) 23 (27%) 2.1 (1.0–4.6) 0.04 23 (27%) 2.1 (1.0–4.6) 0.04
More than two previous UTIs 8 (19%) 13 (15%) 1.2 (0.4–3.3) 0.6 5 (6%) 3.7 (1.1–12.1) 0.03
Structural disease of the urinary or biliary tract 22 (51%) 53 (62%) 0.6 (0.3–1.3) 0.2 11 (13%) 7.1 (2.9–17.0) <0.001
Immunosuppressive drugs 6 (14%) 6 (7%) 2.1 (0.6–7.1) 0.2 1 (1%) 13.7 (1.6–118.5) 0.006
Neutropenia (<1000 WBC ⁄mm3) 6 (14%) 9 (11%) 1.3 (0.4–4.1) 0.5 3 (4%) 4.4 (1.0–18.9) 0.05
Urinary catheter 14 (33%) 15 (17%) 2.2 (0.9–5.3) 0.05 11 (13%) 3.2 (1.3–8.0) 0.007
Venous catheter 20 (47%) 37 (43%) 1.1 (0.5–2.4) 0.7 23 (27%) 2.3 (1.1–5.1) 0.02
Endoscopic procedure 3 (7%) 3 (4%) 2.0 (0.4–10.7) 0.4 0 – 0.03
Surgery 18 (42%) 25 (29%) 1.7 (0.8–3.7) 0.1 13 (15%) 4.0 (1.7–9.4) 0.001
Previous use of any antimicrobial agent 31 (72%) 24 (28%) 6.6 (2.9–15.0) <0.001 19 (22%) 9.1 (3.9–21.0) <0.001
Previous use of aminopenicillins 11 (26%) 12 (14%) 2.1 (0.8–5.3) 0.1 8 (9%) 3.3 (1.2–9.1) 0.01
Previous use of oxyimino-b-lactamsa 11 (26%) 8 (9%) 3.3 (1.2–9.1) 0.01 3 (4%) 9.5 (2.4–36.3) <0.001
Previous use of fluoroquinolones 14 (33%) 6 (7%) 6.4 (2.2–18.3) <0.001 6 (7%) 6.4 (2.2–18.3) <0.001
aOxyimino-b-lactams used were: cefuroxime (two case-patients, one patient in control group 1, no patients in control group 2); cefotaxime or ceftriaxone (8, 4 and 3);
ceftazidime (1, 2 and 0); and aztreonam (0, 1 and 0).
UTI, urinary tract infection; WBC, white blood cells.
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46% and 44%, intra-abdominal infection in 30%
and 31%, respiratory tract in 5% and 8%, soft-
tissue infection in 5% and 6%, and unknown in
14% and 11%, respectively (p 0.8). Similarly,
there were no significant differences in the degree
of clinical severity, with nine (21%) cases and 15
(17%) controls presenting with severe sepsis or
septic shock (OR 1.2, 95% CI 0.4–3.1, p 0.6). Crude
mortality was 21% (11 patients) among cases and
23% (21 patients) among controls (p 0.7).
Variables of interest were analysed in specific
patient subgroups. Median (range) length of
previous hospital stay in the 21 cases and 42 con-
trols with nosocomial bacteraemia was 26 (4–58)
and 12 (3–56) days, respectively (p 0.03). Bacter-
aemia was considered to be healthcare-associated
in 14 (64%) of 22 cases and 20 (45%) of 44 controls
with community-acquired bacteraemia (OR 1.4,
95% CI 0.5–3.5, p 0.4). In addition, three (14%)
cases and one (2%) control were residents in
nursing homes (OR 6.6, 95% CI 0.6–67.9, p 0.1).
Previous studies of risk-factors for bacteraemia
caused by ESBL-producing organisms mostly
concern nosocomial episodes caused by
K. pneumoniae [10–14], but the clinical and molec-
ular epidemiology, sources and predisposing fac-
tors for bacteraemia caused by ESBL-producing
E. coli are completely different [1,2,4]. The present
study revealed that follow-up as an outpatient,
urinary catheterisation and previous use of oxyi-
mino-b-lactams or fluoroquinolones were risk-
factors for ESBL-producing isolates in patients
with bacteraemia caused by E. coli. Furthermore,
a previous extended hospital stay was associated
with ESBL-producing isolates in patients with
nosocomial bacteraemia. The fact that previous
use of oxyimino-b-lactams or fluoroquinolones
was also selected in multivariate analysis using
randomly chosen hospitalised patients indicates
that previous exposure to these antimicrobial
agents are real risk-factors for bloodstream infec-
tions caused by ESBL-producing E. coli [5].
This investigation was a pilot study and thus
has several limitations. Since the study was
carried out in a single centre, the results may
not be applicable in settings with a different
epidemiological context. Also, the small number
of cases did not allow the evaluation of risk-
factors for some subgroups of patients, and might
have been insufficient to detect other relevant
risk-factors; this, in turn, would explain why 14%
of the cases were not exposed to any of the risk-
factors identified. Alternatively, as rectal coloni-
sation with ESBL-producing E. coli is increasing
among healthy individuals [15], it can be hypoth-
esised that infections caused by these organisms
may occur in patients without any specific risk-
factors. A multicentre Spanish study is in pro-
gress with the aim of resolving these questions,
but until more data are available, use of a
carbapenem can be recommended for empirical
treatment of sepsis potentially caused by E. coli in
patients with the identified risk-factors in areas
where ESBL-producing E. coli pose a particular
problem.
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Table 2. Multivariate analysis of
risk-factors for bacteraemia caused
by extended-spectrum b-lactamase-
producing Escherichia colia
Control group 1 Control group 2
OR (95% CI) P OR (95% CI) p
Previous follow-up as an outpatient 2.7 (1.1–6.7) 0.02 – –
Charlson index >2 – – 3.2 (1.2–8.7) 0.01
Structural disease of the urinary or biliary tract – – 6.7 (2.4–18.7) <0.001
Urinary catheter 3.9 (1.1–13.7) 0.03 – –
Previous use of aminopenicillins – – 3.7 (1.0–12.7) 0.03
Previous use of oxyimino-b-lactams 3.9 (1.1–14.1) 0.03 12.3 (2.6–56.7) 0.001
Previous use of fluoroquinolones 6.2 (1.8–20.7) 0.002 5.4 (1.6–18.4) 0.006
aDuration of previous hospital stay was also included in the multivariate models (for community-acquired
episodes, it was considered to be 0).
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ABSTRACT
This study investigated the long-term outcome of
patients with tuberculosis (TB) as a complication
of tumour necrosis factor (TNF)-a blocker ther-
apy. All TB cases (n = 21) complicating TNF-a
blocker therapy from French university hospitals
were collated between January 2000 and Septem-
ber 2002. Outcome was assessed via a postal
questionnaire during September 2005. The mor-
tality rate after 4 years was 4.8%, and one patient
had relapsed and six (29%) patients had recom-
menced TNF-a antagonist treatment, after appro-
priate anti-TB therapy, without reactivation.
These data support the concept that TNF-a
antagonists can be restarted in TB patients pro-
vided that adequate anti-TB treatment has been
completed.
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